In conclusion, we have provided evidence that RFX1 downregulation contributes to the increased IL-17A expression and Th17 cell differentiation in the CD4+ T cells of patients with SLE, as well as promotes the pathologic changes of autoimmune diseases including EAE and lupus-like mice models. This evidence concerns the gene CD4 and autoimmune disease.